Supernus Pharmaceuticals Inc
NASDAQ:SUPN

Watchlist Manager
Supernus Pharmaceuticals Inc Logo
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Watchlist
Price: 45.88 USD -0.61%
Market Cap: 2.6B USD

During the last 3 months Supernus Pharmaceuticals Inc insiders have not bought any shares, and sold 9.5m USD worth of shares. The stock price has dropped by 2% over this period (open performance analysis).

The last transaction was made on Oct 9, 2025 by Newhall Charles W Iii , who sold 1.2m USD worth of SUPN shares.

Last Transactions:
Khattar Jack A.
$-3m
Newhall Charles W Iii
$-1.2m
Khattar Jack A.
$-91.5k
Khattar Jack A.
$-1.9m
Khattar Jack A.
$-414.4k
Khattar Jack A.
$-491.5k
Khattar Jack A.
$-1.4m
Khattar Jack A.
$-779.9k
Mottola Frank
$-229.4k
Khattar Jack A.
$-292.6k
Khattar Jack A.
$-2.6m
Khattar Jack A.
$-1.1m
Khattar Jack A.
$-479.8k
Newhall Charles W Iii
$-161.5k
Newhall Charles W Iii
$-45k
Khattar Jack A.
$-45k
Mottola Frank
$-623.1k
Newhall Charles W Iii
$-63.5k
Dec Timothy C
$-524.1k
Khattar Jack A.
$-67.5k
Hudson Frederick M.
$-315.1k
Sensenig Bethany
$-226.8k
Khattar Jack A.
$-1.5m
Rubin Jonathan
$-36.3k
Bhatt Padmanabh P.
$-376.2k
Bhatt Padmanabh P.
$-27.7k
Bhatt Padmanabh P.
$-101.9k
Bhatt Padmanabh P.
$-321k
Newhall Charles W Iii
$-387.8k
Gemayel Georges
$-391.6k
Khattar Jack A.
$-4.5m
Hudson Frederick M.
$-316.4k
View All Transactions

During the last 3 months Supernus Pharmaceuticals Inc insiders have not bought any shares, and sold 9.5m USD worth of shares. The stock price has dropped by 2% over this period (open performance analysis).

The last transaction was made on Oct 9, 2025 by Newhall Charles W Iii , who sold 1.2m USD worth of SUPN shares.

Sold
0-3
months
9.5m USD
3
3-6
months
8m USD
6
6-9
months
0 USD
0
9-12
months
542.2k USD
2
Bought
0-3
months
0
0 USD
3-6
months
0
0 USD
6-9
months
No Insider Transactions
0
0 USD
9-12
months
0
0 USD

Supernus Pharmaceuticals Inc
Insider Trading Chart

Supernus Pharmaceuticals Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Supernus Pharmaceuticals Inc
Last Insider Transactions

Global
Insiders Monitor

Supernus Pharmaceuticals Inc
Glance View

Supernus Pharmaceuticals Inc. weaves a distinctive narrative within the realm of specialty pharmaceuticals, primarily zeroing in on the development and commercialization of products that address unmet medical needs in central nervous system (CNS) diseases. Founded in 2005 and headquartered in Rockville, Maryland, the company has become a nimble player in the pharmaceutical landscape, leveraging its expertise in product development to create a portfolio that caters to a range of CNS conditions, including epilepsy, migraine, attention-deficit/hyperactivity disorder (ADHD), and bipolar disorder. By focusing on these complex and often challenging areas, Supernus not only pushes the envelope of pharmaceutical innovation but also aligns its mission closely with improving quality of life for patients enduring these conditions. Financially, Supernus drives its revenue through both its proprietary portfolio and strategic partnerships that expand its market reach. Central to its business model is the commercialization of FDA-approved medications such as Trokendi XR and Qelbree, which cater to specific patient needs within the CNS domain. The company's growth is augmented by an adept blend of internal research & development and acquisitions, enabling it to enhance its pipeline and expand its therapeutic offerings. Partnerships and collaborations with other pharmaceutical entities elevate its market penetration, while a solid sales and distribution network ensures its products efficiently reach healthcare providers and patients. This strategic approach allows Supernus to maintain a robust revenue stream while steadily investing in future drug development programs, fostering long-term growth and sustainability within the competitive pharmaceutical sector.

SUPN Intrinsic Value
HIDDEN
Show

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top